Abstract
Angiotensin II (Ang II), the main component of renin-angiotensin system, could mediate pathogenic angiogenesis in cardiovascular disorders. Late endothelial progenitor cells (EPCs) possess potent self-renewal and angiogenic potency superior to early EPCs, but few study focused on the cross-talk between Ang II and late EPCs. We observed that Ang II could increase reactive oxygen species (ROS) and promote capillary formation in late EPCs. Ang II-derived ROS could also upregulate heme oxygenase-1 (HO-1) expression, and treating late EPCs with HO-1 small interfering RNA or heme oxygenase inhibitor (HO inhibitor) could inhibit Ang II-induced tube formation and increase ROS level and apoptosis rate. In addition, PD98059 and LY294002 pretreatment attenuated Ang II-induced HO-1 expression. Accordingly, Ang II-derived ROS could promote angiogenesis in late EPCs by inducing HO-1 expression via ERK1/2 and AKT/PI3K pathways, and we believe HO-1 might be a promising intervention target in EPCs due to its potent proangiogenic, antioxidant, and antiapoptosis potentials.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10753-013-9806-9/MediaObjects/10753_2013_9806_Fig1_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10753-013-9806-9/MediaObjects/10753_2013_9806_Fig2_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10753-013-9806-9/MediaObjects/10753_2013_9806_Fig3_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10753-013-9806-9/MediaObjects/10753_2013_9806_Fig4_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10753-013-9806-9/MediaObjects/10753_2013_9806_Fig5_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10753-013-9806-9/MediaObjects/10753_2013_9806_Fig6_HTML.gif)
Similar content being viewed by others
References
Ferrario, C.M., and W.B. Strawn. 2006. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. American Journal of Cardiology 98: 121–128.
Nicholls, M.G., A.M. Richards, and M. Agarwal. 1998. The importance of the renin-angiotensin system in cardiovascular disease. Journal of Human Hypertension 12: 295–299.
Egami, K., T. Murohara, T. Shimada, K. Sasaki, S. Shintani, T. Sugaya, M. Ishii, T. Akagi, H. Ikeda, T. Matsuishi, and T. Imaizumi. 2003. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. Journal of Clinical Investigation 112: 67–75.
Suganuma, T., K. Ino, K. Shibata, H. Kajiyama, T. Nagasaka, S. Mizutani, and F. Kikkawa. 2005. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clinical Cancer Research 11: 2686–2694.
Heffelfinger, S.C. 2007. The renin angiotensin system in the regulation of angiogenesis. Current Pharmaceutical Design 13: 1215–1229.
Otani, A., H. Takagi, H. Oh, S. Koyama, and Y. Honda. 2001. Angiotensin II induces expression of the Tie2 receptor ligand, angiopoietin-2, in bovine retinal endothelial cells. Diabetes 50: 867–875.
Sasaki, K., T. Murohara, H. Ikeda, T. Sugaya, T. Shimada, S. Shintani, and T. Imaizumi. 2002. Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis. Journal of Clinical Investigation 109: 603–611.
De Giusti, V.C., C.D. Garciarena, and E.A. Aiello. 2009. Role of reactive oxygen species (ROS) in angiotensin II-induced stimulation of the cardiac Na+/HCO3- cotransport. Journal of Molecular and Cellular Cardiology 47: 716–722.
Touyz, R.M. 2004. Reactive oxygen species and angiotensin II signaling in vascular cells—implications in cardiovascular disease. Brazilian Journal of Medical and Biological Research 37: 1263–1273.
Feliers, D., Y. Gorin, G. Ghosh-Choudhury, H.E. Abboud, and B.S. Kasinath. 2006. Angiotensin II stimulation of VEGF mRNA translation requires production of reactive oxygen species. American Journal of Physiology. Renal Physiology 290: F927–F936.
Uemura, H., H. Ishiguro, Y. Ishiguro, K. Hoshino, S. Takahashi, and Y. Kubota. 2008. Angiotensin II induces oxidative stress in prostate cancer. Molecular Cancer Research 6: 250–258.
Pelliccia, F., C. Cianfrocca, G. Rosano, G. Mercuro, G. Speciale, and V. Pasceri. 2010. Role of endothelial progenitor cells in restenosis and progression of coronary atherosclerosis after percutaneous coronary intervention: a prospective study. JACC. Cardiovascular Interventions 3: 78–86.
Hirschi, K.K., D.A. Ingram, and M.C. Yoder. 2008. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arteriosclerosis, Thrombosis, and Vascular Biology 28: 1584–1595.
Ribatti, D. 2004. The involvement of endothelial progenitor cells in tumor angiogenesis. Journal of Cellular and Molecular Medicine 8: 294–300.
Gao, D., D.J. Nolan, A.S. Mellick, K. Bambino, K. McDonnell, and V. Mittal. 2008. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 319: 195–198.
Rehman, J., J. Li, C.M. Orschell, and K.L. March. 2003. Peripheral blood “endothelial progenitor cells” are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 107: 1164–1169.
Hur, J., C.H. Yoon, H.S. Kim, J.H. Choi, H.J. Kang, K.K. Hwang, B.H. Oh, M.M. Lee, and Y.B. Park. 2004. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology 24: 288–293.
Endtmann, C., T. Ebrahimian, T. Czech, O. Arfa, U. Laufs, M. Fritz, K. Wassmann, N. Werner, V. Petoumenos, G. Nickenig, and S. Wassmann. 2011. Angiotensin II impairs endothelial progenitor cell number and function in vitro and in vivo: implications for vascular regeneration. Hypertension 58: 394–403.
Imanishi, T., T. Hano, and I. Nishio. 2004. Angiotensin II potentiates vascular endothelial growth factor-induced proliferation and network formation of endothelial progenitor cells. Hypertension Research 27: 101–108.
Sanada, F., Y. Taniyama, J. Azuma, K. Iekushi, N. Dosaka, T. Yokoi, N. Koibuchi, H. Kusunoki, Y. Aizawa, and R. Morishita. 2009. Hepatocyte growth factor, but not vascular endothelial growth factor, attenuates angiotensin II-induced endothelial progenitor cell senescence. Hypertension 53: 77–82.
Roks, A.J., and I.I. Angiotensin. 2011. Deteriorates endothelial progenitor cells: good intentions with bad consequences. Hypertension 58: 356–358.
Yin, T., X. Ma, L. Zhao, K. Cheng, and H. Wang. 2008. Angiotensin II promotes NO production, inhibits apoptosis and enhances adhesion potential of bone marrow-derived endothelial progenitor cells. Cell Research 18: 792–799.
Aizawa, T., N. Ishizaka, J. Taguchi, R. Nagai, I. Mori, S.S. Tang, J.R. Ingelfinger, and M. Ohno. 2000. Heme oxygenase-1 is upregulated in the kidney of angiotensin II-induced hypertensive rats: possible role in renoprotection. Hypertension 35: 800–806.
Dulak, J., J. Deshane, A. Jozkowicz, and A. Agarwal. 2008. Heme oxygenase-1 and carbon monoxide in vascular pathobiology: focus on angiogenesis. Circulation 117: 231–241.
Sunamura, M., D.G. Duda, M.H. Ghattas, L. Lozonschi, F. Motoi, J. Yamauchi, S. Matsuno, S. Shibahara, and N.G. Abraham. 2003. Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer. Angiogenesis 6: 15–24.
Deshane, J., S. Chen, S. Caballero, A. Grochot-Przeczek, H. Was, C.S. Li, R. Lach, T.D. Hock, B. Chen, N. Hill-Kapturczak, G.P. Siegal, J. Dulak, A. Jozkowicz, M.B. Grant, and A. Agarwal. 2007. Stromal cell-derived factor 1 promotes angiogenesis via a heme oxygenase 1-dependent mechanism. Journal of Experimental Medicine 204: 605–618.
Berberat, P.O., Z. Dambrauskas, A. Gulbinas, T. Giese, N. Giese, B. Kunzli, F. Autschbach, S. Meuer, M.W. Buchler, and H. Friess. 2005. Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment. Clinical Cancer Research 11: 3790–3798.
Hanna, I.R., Y. Taniyama, K. Szocs, P. Rocic, and K.K. Griendling. 2002. NAD(P)H oxidase-derived reactive oxygen species as mediators of angiotensin II signaling. Antioxidants and Redox Signaling 4: 899–914.
Imanishi, T., T. Hano, and I. Nishio. 2005. Angiotensin II accelerates endothelial progenitor cell senescence through induction of oxidative stress. Journal of Hypertension 23: 97–104.
Dandapat, A., C. Hu, L. Sun, and J.L. Mehta. 2007. Small concentrations of oxLDL induce capillary tube formation from endothelial cells via LOX-1-dependent redox-sensitive pathway. Arteriosclerosis, Thrombosis, and Vascular Biology 27: 2435–2442.
Ushio-Fukai, M. 2006. Redox signaling in angiogenesis: role of NADPH oxidase. Cardiovascular Research 71: 226–235.
Circu, M.L., and T.Y. Aw. 2010. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radical Biology and Medicine 48: 749–762.
Wu, B.J., R.G. Midwinter, C. Cassano, K. Beck, Y. Wang, D. Changsiri, J.R. Gamble, and R. Stocker. 2009. Heme oxygenase-1 increases endothelial progenitor cells. Arteriosclerosis, Thrombosis, and Vascular Biology 29: 1537–1542.
Lin, H.H., Y.H. Chen, S.F. Yet, and L.Y. Chau. 2009. After vascular injury, heme oxygenase-1/carbon monoxide enhances re-endothelialization via promoting mobilization of circulating endothelial progenitor cells. Journal of Thrombosis and Haemostasis 7: 1401–1408.
Hur, J., C.H. Yoon, C.S. Lee, T.Y. Kim, I.Y. Oh, K.W. Park, J.H. Kim, H.S. Lee, H.J. Kang, I.H. Chae, B.H. Oh, Y.B. Park, and H.S. Kim. 2007. Akt is a key modulator of endothelial progenitor cell trafficking in ischemic muscle. Stem Cells 25: 1769–1778.
Friedrich, E.B., C. Werner, K. Walenta, M. Bohm, and B. Scheller. 2009. Role of extracellular signal-regulated kinase for endothelial progenitor cell dysfunction in coronary artery disease. Basic Research in Cardiology 104: 613–620.
Wang, J.Y., Y.T. Lee, P.F. Chang, and L.Y. Chau. 2009. Hemin promotes proliferation and differentiation of endothelial progenitor cells via activation of AKT and ERK. Journal of Cellular Physiology 219: 617–625.
Khurana, R., M. Simons, J.F. Martin, and I.C. Zachary. 2005. Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation 112: 1813–1824.
Virmani, R., F.D. Kolodgie, A.P. Burke, A.V. Finn, H.K. Gold, T.N. Tulenko, S.P. Wrenn, and J. Narula. 2005. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arteriosclerosis, Thrombosis, and Vascular Biology 25: 2054–2061.
Acknowledgments
This study was supported by a grant from the National Natural Science Foundation of China (nos. 81100101 and 81270212), Yat-sen Scholarship for Young Scientist, and Young Teacher Support Project by Sun Yat-sen University for Chen Yangxin.
Author information
Authors and Affiliations
Corresponding authors
Additional information
**gting Mai and Qiong Qiu contributed equally to this paper.
ELECTRONIC SUPPLEMENTARY MATERIAL
Below is the link to the electronic supplementary material.
Fig. SI
VEGFR-2 and p-NOS levels were investigated in early and late EPCs after exposure to Ang II. The qRT-PCR was used to examine mRNA expression of VEGFR-2 (A) and protein level was examined by flow cytometry (B). Protein levels of p-eNOS (Ser1177) were tested by western blot. Protein levels of p-eNOS were normalized to the housekee** protein beta-tubulin (C). Three independent experiments were performed. qRT-PCR results are expressed as mean ± SEM and presented by percentage of the control group. *P < 0.05 compared to control group (JPEG 47 kb)
Fig. SII
PEG-SOD was an appropriate antioxidant for abolishing the ROS induced by Ang II in late EPCs. (A) Intracellular ROS was detected by means of an oxidation-sensitive fluorescent probe (DCFH-DA) used flow cytometry. Late EPCs were exposed to Ang II (100 nM) for 48 h with vehicle or PEG-SOD (50 U/ml), N-acetyl-l-cysteine (NAC; 10 mM) and apocynin (selective inhibitor of NADPH oxidase;100 μM) (n = 3). (B) Effects of NAC and PEG-SOD in the angiogenesis function were examined. Late EPCs were treated with vehicle or with NAC or PEG-SOD for 24 h (n = 3). Results are expressed as mean ± SEM and presented by percentage of the control group (JPEG 28 kb)
Fig. SIII
Ang II stimulated HO-1 expression in late EPCs. The qRT-PCR showed HO-1 mRNA levels for indicated concentrations (0.1, 1, 10, 100 nM) (A) and time (4, 12, 24 h) (B) under Ang II stimulation (n = 3). # P < 0.05 compared to control group; * P < 0.05 compared to Ang 100 nM 12 h group. Western blots showed HO-1 protein levels for indicated concentrations (1, 10 nM, 100 nM, 1,000 mM) (C) and time (12, 24, 36, and 48 h) (D) under Ang II stimulation (n = 3). Data were normalized to the housekee** protein beta-tubulin # P < 0.05 compared to control group; * P < 0.05 compared to Ang 100 nM 24-h group. Results are expressed as mean ± SEM and presented by percentage of the control group. # P < 0.05 compared to control group (JPEG 69 kb)
Fig. SIV
HO-1 siRNA transfection effectively suppress Ang II-induced HO-1 expression and HO-1 inducer CoPPIX could significantly upregulate HO-1 expression in late EPCs. (A) PE conjugated HO-1 siRNA were used to elevate the transfection efficiency by fluorescence microscopy. HO-1 mRNA (C) and protein (D) expression were evaluated. Late EPCs were exposed to Ang II (100 nM) in presence of HO-1 siRNA (100 nM) or mock siRNA (100 nM). Cells were also treated with CoPPIX (50 μmol/L) alone. Protein levels of HO-1 were normalized to the housekee** protein beta-tubulin. Three independent experiments were performed. Results are expressed as mean ± SEM and presented by percentage of the control group. # P < 0.05 compared to control group. * P < 0.05 compared to Ang II group (JPEG 60 kb)
Fig. SV
Representative immunoblot showed p-ERK/ERK, p-AKT(Ser473)/AKT, p-p38/p38, p-JNK/JNK amounts of EPCs in response to Ang II for indicated time (0, 24, 48, and 72 h). VEGF was added to maintain the vitality of EPCs in every group, n = 3). Data were normalized to the housekee** protein GAPDH. # P < 0.05 compared to control group (JPEG 37 kb)
Rights and permissions
About this article
Cite this article
Mai, J., Qiu, Q., Lin, Y.Q. et al. Angiotensin II-Derived Reactive Oxygen Species Promote Angiogenesis in Human Late Endothelial Progenitor Cells Through Heme Oxygenase-1 via ERK1/2 and AKT/PI3K Pathways. Inflammation 37, 858–870 (2014). https://doi.org/10.1007/s10753-013-9806-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10753-013-9806-9